Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Trodelvy
Pharma
Gilead unfolds Trodelvy triplet's first-line NSCLC data
Gilead argues that the Trodelvy-Keytruda-chemo data support the company's ongoing phase 3 trial for a doublet without chemo.
Angus Liu
Sep 9, 2024 1:45pm
Merck, AstraZeneca, Gilead: The race for supremacy in an ADC field
Aug 2, 2024 4:00pm
ASCO: Gilead seeks silver lining in Trodelvy’s failed NSCLC trial
May 31, 2024 8:00am
Gilead's Trodelvy suffers double whammy
May 30, 2024 6:20pm
Gilead writes $2.4B off Trodelvy as CEO underscores focus
Apr 26, 2024 11:21am
Teva snares up to $150M in Abingworth funding for inhaler program
Apr 1, 2024 10:51am
